Which endometrial cancers do you choose to send POLE testing on, assuming you cannot check it on everyone?

Only those where it would change my treatment. Mostly high-intermediate risk, where I’d spare them VBT or not.

This is a great question for two main reasons:

1. Resource utilization
2. What am I going to do with the data

I would choose to send POLE testing on patients where you think the data might impact your care... the challenge with that is that we lack strong prospective data to support de-escalation. With th...

I hear Dr. @Dr. First Last argument. However, I am a simple person...when available, I think we should test everyone and follow the algorithm. That will minimize variability down the road if and when the patient recurs.